Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Picard Medical, Inc. (PMI) is a medical device company focused on developing innovative solutions for cardiac surgery, particularly in the area of perfusion technology. The company's unique competitive advantage lies in its proprietary blood management systems, which enhance patient outcomes and reduce complications during surgery. PMI primarily operates in the North American market, targeting hospitals and surgical centers.
PMI generates revenue through the sale of its proprietary perfusion devices and related consumables, which are critical in cardiac surgeries. The company benefits from a strong pricing power due to the specialized nature of its products and the high demand for improved surgical outcomes, allowing for premium pricing.
Regulatory approvals for new devices
Trends in cardiac surgery volumes
Partnerships with hospitals and surgical centers
Technological advancements in perfusion systems
Technological disruption from new entrants in the medical device market
Regulatory changes affecting device approvals and market access
Emergence of alternative perfusion technologies from competitors
Price competition from larger medical device manufacturers
High operating losses leading to liquidity concerns
Negative cash flow impacting ability to fund operations and growth
moderate - PMI's performance is somewhat linked to the overall healthcare spending, which can be influenced by GDP growth and consumer spending on medical services.
Interest rates affect PMI's financing costs for R&D and expansion. Higher rates could lead to increased costs of capital, impacting profitability and valuation multiples.
minimal - PMI does not rely heavily on credit for its operations, given its negative debt/equity ratio.
growth - investors looking for high potential returns from innovative medical technologies.
high - PMI's stock has shown significant volatility, evidenced by a 96.5% decline over the past year.